Literature DB >> 11844942

A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type.

Franny C Moene1, Philip Spinhoven, Kees A L Hoogduin, Richard van Dyck.   

Abstract

BACKGROUND: The primary aim of this study was threefold: (1) to examine the additional effects of hypnosis aimed at symptom reduction, using symptom-oriented and expression- and insight-oriented techniques in a comprehensive clinical treatment programme for in-patients with a persistent conversion disorder of the motor type; (2) to assess whether the level of hypnotisability was predictive of treatment outcome, and (3) to explore the efficacy of the total clinical treatment programme.
METHODS: The study population consisted of 45 in-patients between 18 and 65 years of age meeting the DSM-III-R criteria for conversion disorder of the motor type or somatisation disorder with motor conversion symptoms. A randomised controlled clinical trial was undertaken. The primary outcome measures were the Video Rating Scale for Motor Conversion Symptoms, the D(isabilities) code items from the International Classification of Impairments, Disabilities and Handicaps and the Symptom Checklist-90. Measures of the credibility of treatment and patient expectations of treatment outcome were used as manipulation checks. Hypnotisability was measured using the Stanford Hypnotic Clinical Scale.
RESULTS: Significant treatment results for all outcome measures were found for the total sample. These effects proved to be clinically significant. The use of hypnosis had no additional effect on treatment outcome. Hypnotisability was not predictive of treatment outcome.
CONCLUSION: A comprehensive treatment programme, either with or without hypnosis, can be worthwhile for patients with long-standing conversion symptoms. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11844942     DOI: 10.1159/000049348

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  26 in total

Review 1.  [Conversion disorders. From neurobiology to treatment].

Authors:  C Schönfeldt-Lecuona; B J Connemann; A Höse; M Spitzer; H Walter
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

Review 2.  Conversion Disorder- Mind versus Body: A Review.

Authors:  Shahid Ali; Shagufta Jabeen; Rebecca J Pate; Marwah Shahid; Sandhya Chinala; Milankumar Nathani; Rida Shah
Journal:  Innov Clin Neurosci       Date:  2015 May-Jun

Review 3.  Conversion disorder: advances in our understanding.

Authors:  Anthony Feinstein
Journal:  CMAJ       Date:  2011-04-18       Impact factor: 8.262

4.  Treatment of functional motor disorders.

Authors:  Jeannette M Gelauff; Yasmine E M Dreissen; Marina A J Tijssen; Jon Stone
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.598

Review 5.  Conversion Disorder, Functional Neurological Symptom Disorder, and Chronic Pain: Comorbidity, Assessment, and Treatment.

Authors:  Patricia Tsui; Andrew Deptula; Derek Y Yuan
Journal:  Curr Pain Headache Rep       Date:  2017-06

Review 6.  Treatment of functional (psychogenic) movement disorders.

Authors:  Luciana Ricciardi; Mark J Edwards
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  The impact of hypnotic suggestibility in clinical care settings.

Authors:  Guy H Montgomery; Julie B Schnur; Daniel David
Journal:  Int J Clin Exp Hypn       Date:  2011-07

8.  The 12 year prognosis of unilateral functional weakness and sensory disturbance.

Authors:  J Stone; M Sharpe; P M Rothwell; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

9.  Treatment of conversion disorder in the 21st century: have we moved beyond the couch?

Authors:  Patricia I Rosebush; Michael F Mazurek
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

10.  A Therapeutic Approach to Psychogenic Nonepileptic Seizures.

Authors:  M Ayman Haykal; Brien Smith
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.